Innovating Works

EPOS IASIS

Desconocido
RealCare: Real-time biomarker detection systems for rapid medical decision-making in cancer and cardiac diseas... E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 RealCare is a cutting-edge research initiative focused on developing and validating next-generation point-of-care (PoC) systems that detect...
2023-11-17 - 2028-11-30 | Financiado
PRIME: A Personalised Living Cell Synthetic Computing Circuit for Sensing and Treating Neurodegenerative Di... E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD participó en un H2020: H2020-FETOPEN-2018-2020 There remain urgent and unmet needs for the treatment of neurological diseases. Epilepsy is a serious, chronic brain disease characterized b...
2021-01-19 - 2025-01-31 | Financiado
DIGIPREDICT: Edge AI deployed DIGItal Twins for PREDICTing disease progression and need for early intervention in... E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD participó en un H2020: H2020-FETPROACT-2018-2020 The interplay between viral infection, host response, development of (hyper)inflammation and cardiovascular injury in COVID-19 is currently...
2020-12-08 - 2024-12-31 | Financiado
GLADIATOR: Next generation theranostics of brain pathologies with autonomous externally controllable nanonetwor... E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD participó en un H2020: H2020-FETOPEN-2018-2020 Brain pathologies are highly complex disorders. Despite recent progress, their prognosis is grim, defining a high societal challenge. Bridgi...
2018-12-17 - 2023-09-30 | Financiado
NANORESISTANCE: Management of Resistance to Tyrosine Kinase Inhibitors with Advanced Nanosystems E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD tramitó un FP7: NANORESISTANCE introduces for the first time (i) receptor -independent targeting of Epidermal Growth Factor Receptor-kinase activity, (ii) n...
Financiado
PathChooser: Innovative mechanistic based strategies for delivery of therapeutic macromolecules across cellular... E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD participó en un FP7: Nanomedicine offers capability to significantly change the course of treatment for life-threatening diseases. Many of the most significant c...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.